University of Pennsylvania

University Patents, Inc.

Competitive Technologies, Inc.

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Northwestern University

University of Pittsburgh

Juvaris Biotherapeutics, Inc.

National Institutes of Health

Gary H Cohen

Roselyn J Eisenberg

Bernard Moss

Drew Weissman

Harvey M Friedman

Patricia G Spear

Rebecca I Montgomery

Sita Awasthi

Gary Dubin

John Charles Whitbeck

Lydia Aldaz-Carroll

Tao Peng

Shlomo Lustig

Anthony Nicola

Christiana Fogg

John D Lambris

Joseph C Glorioso, Iii

Justus B Cohen

Jeffery Fairman

Robert J Geraghty

Morgyn S Warner

Roselyn J Eisenbert

Wanda M Martinez

Claude Krummenacher

Charles J Whitbeck

Roselyn T Eisenberg

Doina Atanasiu

Tina Marie Cairns

Bonnie Lynn Hall

Ceren Tuzmen

Maria Rosa Sarrias

Lydia Aldaz-Carrol

Christina Fogg

Provided herein are antigenically stealthed HSV particles, and methods of use of the antigenically-stealthed HSV particles.

Antigenically stealthed oncolytic viruses

Compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified m RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.

Subunit vaccines for herpes viruses and methods of use

The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.

Compositions, methods and kits relating to poxvirus subunit vaccines

The invention includes antiherpesviral peptides and method of generating the same.

Peptides for inhibition of herpes simplex virus entry

A cellular herpesvirus entry protein, or a mutant, a homolog, a derivative, a variant or a biologically active fragment thereof, suspended in a pharmaceutically active carrier in an amount effective to inhibit entry of an alphaherpesvirus into a cell, wherein the cellular herpesvirus entry protein is a member of the immunoglobulin superfamily, is provided and method of use thereof

Cellular proteins which mediate herpesvirus entry

The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.

Soluble herpesvirus glycoprotein complex vaccine

Herpes simplex virus glycoprotein D variants

The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When expressed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 2 and the preferred DNA sequence encoding gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 1. Administration of gD variant molecules of the invention to mammalian subjects, especially humans, for the purpose of preventing HSV infection and/or ameliorating pathological sequelae of HSV infection is specifically contemplated.

Disclosed are diagnostic reagents for use in detection of Herpes Simplex Virus Type 1 antibodies or Herpes Simplex Virus Type 2 antibodies comprising novel Herpes Simplex Virus envelope glycoproteins gD-1 and gD-2, immunologically active fragments thereof, immunologically synthetic replicas, thereof, and specific polypeptides comprising specific amino acid sequences.

Diagnostic reagents relating to herpes simplex virus

Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunoadsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid sequences which are: (1) substantially common to both gD-1 and gD-2; cumulatively hydrophilic in nature; and (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification.

Materials and methods for herpes simplex virus vaccination

Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)]. Disclosed also are novel procedures for detection, quantification and isolation by affinity purification of gD-1, gD-2 and structurally related compounds.

Herpes virus specific immunological materials and methods

Growing community of inventors

Havertown, PA, United States of America

Gary H Cohen